611 W. Union Street
Benson, AZ 85602
(520) 586-0800

LaFrontera
member support line
1-520-279-5737
M-F 5pm-8pm
24/7 weekends/holidays

AzCH Nurse Assist Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530



SEABHS
611 W. Union Street
Benson, AZ 85602
(520) 586-0800

AzCH Nurse Assist Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530


powered by centersite dot net
Cancer
Resources
Basic InformationLatest News
You Don't Have to Smoke to Get Lung CancerSide Effects From New Cancer Meds Have Silver LiningVA Study Shows Black Men Twice as Likely to Develop Prostate Cancer as WhitesColonoscopy Surprise Bills Should Be Thing of the Past, Experts SayNewer Hormone Treatments for Prostate Cancer May Raise Risk of DepressionYou Don't Have to Be a Smoker to Get Lung CancerImmune-Based Drug Fights Advanced Endometrial Cancer: StudyProgress on Lung Cancer Drives Overall Decline in U.S. Cancer DeathsMedicaid Rules May Affect Americans' Cancer SurvivalToo Much Sitting Could Mean Worse Outcomes for Cancer SurvivorsDrug Combo Boosts Outcomes for Advanced MelanomaKnow Your Thyroid FactsYou Can Help Prevent Cervical CancerQuitting Smoking Ups Survival After Lung Cancer DiagnosisMany Cancer Patients Face Mounting Bills Despite Having InsuranceMore Than 10 Million People Died of Cancer Worldwide in 2019Black Men Get Better Outcomes From Radiation Rx for Prostate CancerNew Clues to How Ovarian Cancer Begins -- and Might Be Prevented'Breakthrough' COVID Infections Can Still Be Deadly for Cancer PatientsCould a High-Fiber Diet Help Boost Cancer Survival?Coping With Cancer and COVID During the HolidaysHPV Vaccination Could Rid U.S. of Most Mouth, Throat Cancers in MenCT Lung Cancer Screening Saved His Life, and Could Do So for MoreProgram Aims to Get Lifesaving Drugs to Kids With Cancer in Poorer CountriesThroat Cancers Tied to HPV Are Rising Among U.S. Men, WomenSupplements: Many Cancer Patients Think They'll Help, But Experts Urge CautionOver 60? You Have Billions of Potentially Cancer-Causing CellsDrug Combo May Fight a Tough Form of Breast CancerCOVID Vaccines Offer Only Some Protection for People Battling MyelomaDrug Can Keep Leukemia in Remission for Years in Younger PatientsNew Treatment Greatly Boosts Survival for Kids With a Rare, Aggressive CancerFear Keeps Some Cancer Patients From Getting COVID VaccineNew Hormonal Pill May Boost Outcomes for Older Breast Cancer PatientsBlack Women Have Triple the Odds for Lymphedema After Breast Cancer SurgeryWere Cancer Patients Neglected in U.S. COVID Vaccine Rollout?More Evidence That Pandemic Delayed Cancer DiagnosesDo Immune-Based Cancer Drugs Work Better in Men?Gene Test Spots Breast Cancer Patients Who Can Skip Post-Op ChemoOld Spice, Secret Antiperspirants Recalled Due to BenzeneClinical Trials Are Becoming More Diverse, But There's Still Work To DoFDA Approves Imaging Drug That Can Help Surgeons Spot Ovarian CancersA Routine Skin Check Could Save Your LifeWhat You Need to Know About Stomach CancerCOVID Booster Shot Helps Cancer PatientsLung Cancer Survival Continues to Improve, But Not for AllBreast Cancer Diagnosis Linked to Higher Odds for Dangerous A-FibDrug Used to Prevent Miscarriage May Raise Lifetime Cancer Risk in OffspringMore Evidence That COVID Vaccines Are Safe for Cancer PatientsExercise Helps Ease Arm, Shoulder Pain After Breast Cancer Surgery50 Years On, Real Progress in War Against Cancer
LinksBook ReviewsSelf-Help Groups
Related Topics

Medical Disorders
Pain Management

Immune-Based Drug Fights Advanced Endometrial Cancer: Study

HealthDay News
by Cara Murez
Updated: Jan 13th 2022

new article illustration

THURSDAY, Jan. 13, 2022 (HealthDay News) -- A drug used to treat several types of cancer is also an effective treatment for aggressive forms of endometrial cancer, the second most common cancer in women worldwide, a new clinical trial shows. The endometrium is the inner lining of the uterus.

"These findings suggest a long-term benefit to patients," said lead researcher Dr. David O'Malley, a gynecologic oncologist at the Ohio State University Comprehensive Cancer Center, in Columbus. "Even the potential for curative intent is now possible in patients with recurrent or metastatic uterine cancer."

Pembrolizumab, marketed as Keytruda, inhibits cellular receptors that prevent the immune system from recognizing and destroying cancer cells. It is already used to treat melanoma, lung, head/neck, cervical and stomach cancers.

This mid-stage clinical trial included 90 women in 15 countries with recurrent or advanced endometrial cancer. Their cancers were MMR deficient (dMMR) or MSI-high tumors, meaning they behave abnormally.

According to the new report, 48% of patients with advanced endometrial cancer experienced a complete or partial response to treatment. In two-thirds, the response lasted more than three years. Two-thirds of all patients in the study had a measurable response to treatment. The median follow-up was about 3.5 years — meaning half were followed for a shorter time, half longer.

The findings are timely because rates of endometrial cancer are on the rise. The cancer begins in the tissue lining the uterus. Platinum-based chemo drugs can be effective, but in many cases, cancer returns, the study authors noted in a university news release.

Effective therapies for cancer that has returned or spread are limited, according to the study team. As a result, the five-year survival rate for women with advanced or recurrent endometrial cancer is 17%.

Up to 31% of patients with endometrial cancer have changes in DNA known as microsatellite instability (MSI-H) and mismatch repair deficiency (dMMR). The change is usually present in the tumor and is not a genetic mutation, O'Malley noted.

"By targeting this damaged pathway with this targeted drug, we can reset the cellular mechanisms and allow the immune system to reactivate and attack the cancer cells," O'Malley said.

The researchers noted that before this study, there was no standard-of-care second-line therapy for endometrial cancer patients with MSI-H/dMMR-positive tumors. They said the response for this treatment is very strong overall when compared to the expected 10% to 15% response rate to the most often used second-line chemotherapy treatments.

The findings were published online recently in the Journal of Clinical Oncology.

Merck, which makes pembrolizumab, sponsored the study.

More information

The U.S. National Cancer Institute has more on endometrial cancer.

SOURCE: Ohio State University Wexner Medical Center, news release, Jan. 6, 2022